Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.
Abstract
Inflammatory breast cancer (IBC) is an understudied and aggressive form of breast
cancer with a poor prognosis, accounting for 2-6% of new breast cancer diagnoses but
10% of all breast cancer-related deaths in the United States. Currently there are
no therapeutic regimens developed specifically for IBC, and it is critical to recognize
that all aspects of treating IBC - including staging, diagnosis, and therapy - are
vastly different than other breast cancers. In December 2014, under the umbrella of
an interdisciplinary initiative supported by the Duke School of Medicine, researchers,
clinicians, research administrators, and patient advocates formed the Duke Consortium
for IBC to address the needs of patients in North Carolina (an ethnically and economically
diverse state with 100 counties) and across the Southeastern United States. The primary
goal of this group is to translate research into action and improve both awareness
and patient care through collaborations with local, national and international IBC
programs. The consortium held its inaugural meeting on Feb 28, 2018, which also marked
Rare Disease Day and convened national research experts, clinicians, patients, advocates,
government representatives, foundation leaders, staff, and trainees. The meeting focused
on new developments and challenges in the clinical management of IBC, research challenges
and opportunities, and an interactive session to garner input from patients, advocates,
and community partners that would inform a strategic plan toward continuing improvements
in IBC patient care, research, and education.
Type
Journal articleSubject
advocacybreast cancer
community engagement
inflammatory breast cancer
orphan disease
patient-centered
Permalink
https://hdl.handle.net/10161/19129Published Version (Please cite this version)
10.7150/jca.31176Publication Info
Devi, Gayathri R; Hough, Holly; Barrett, Nadine; Cristofanilli, Massimo; Overmoyer,
Beth; Spector, Neil; ... Marcom, P Kelly (2019). Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and
Community Engagement from the Duke IBC Consortium. Journal of Cancer, 10(15). pp. 3344-3351. 10.7150/jca.31176. Retrieved from https://hdl.handle.net/10161/19129.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Nadine J Barrett
Associate Professor in Family Medicine and Community Health
Dr. Nadine J. Barrett is an Associate Professor in the Department of Family Medicine
and Community Health at Duke University. She currently hold senior leadership roles
as CTSI Co-Director for Equity and Stakeholder Strategy and the Inaugural Director
of The Center for Equity in Research in the Duke Clinical Translational Science Institute,
and Associate Director for Equity and Stakeholder Strategy, Duke Cancer Institute.
A medical sociologist by training, Dr. Barrett is
Susan Faye Dent
Professor of Medicine
Medical Oncologist with a focus on breast cancerAssociate Director of Breast Cancer
Clinical ResearchCo-Director Duke Cardio-Oncology Program
Gayathri R. Devi
Professor in Surgery
Dr. Devi’s research interests include functional genomics, anti-cancer drug discovery
and development, mechanisms of cancer cell signaling, tumor immunity and applications
thereof for overcoming therapeutic resistance in cancer. The lab has established
prostate, inflammatory breast cancer and ovarian cellular and tumor models.
Oluwadamilola Motunrayo Fayanju
Associate Professor of Surgery
Dr. Fayanju is an Associate Professor of Surgery and Population Health Sciences in
the Duke University School of Medicine, Associate Director for Disparities & Value
in Healthcare with Duke Forge (the university’s center for actionable data science:
https://forge.duke.edu/oluwadamilola-fayanju-md-ma-mphs), and Director of the Durham
VA Breast Clinic. She received her undergraduate degree in History and
Jeremy M Force
Assistant Professor of Medicine
Holly Hough
Dir, Office for Physician Scientist Dev
Eun-Sil Shelley Hwang
Mary and Deryl Hart Distinguished Professor of Surgery, in the School of Medicine
John P. Kirkpatrick
Professor of Radiation Oncology
Malignant and benign tumors of the brain, spine and base of skull. Mathematical modelling
of tumor metabolism, mass transfer and the response to ionizing radiation. Enhancing
clinical outcome in stereotactic radiosurgery, fractionated stereotactic radiotherapy
and stereotactic body radiotherapy.
Paul Kelly Marcom
Adjunct Professor in the Department of Medicine
Basic Science: -Germline and somatic genetic changes in breast cancer. Translational:
-Identification and management of individuals and families with hereditary cancer
risk. -Communication of cancer risk information to individuals and families. -Breast
cancer prevention. -Optimizing management of early breast cancer. -Treatment of metastatic
breast cancer Clinically, Dr. Marcom works as a medical oncologist in the multidisciplina
Shannon Jones McCall
Associate Professor of Pathology
As Vice Chair for Translational Research in the Department of Pathology, I am involved
in numerous translational cancer research projects that rely on the study of human
biological samples. I am the director of the Duke BioRepository & Precision Pathology
Center (Duke BRPC), a shared resource of the School of Medicine and the Duke Cancer
Institute. I serve as the PI for the National Cancer Institute's Cooperative Human
Tissue Network Southern Division (a five-year UM1 grant), whi
Gregory M. Palmer
Associate Professor of Radiation Oncology
Greg Palmer obtained his B.S. in Biomedical Engineering from Marquette University
in 2000, after which he obtained his Ph.D. in BME from the University of Wisconsin,
Madison. He is currently an Associate Professor in the Department of Radiation Oncology,
Cancer Biology Division at Duke University Medical Center. His primary research focus
has been identifying and exploiting the changes in absorption, scattering, and fluorescence
properties of tissue associated with cancer progression and therape
Steven Patierno
Charles D. Watts Distinguished Professor of Medicine
Patierno's current translational research interests are focused on the genomics molecular
biology of cancer disparities, cancer biology, molecular pharmacology and targeted
experimental therapeutics to control prostate, breast and lung tumor aggressiveness. He
is an internationally recognized expert in cancer control, cancer causation and molecular
carcinogenesis, which includes a broad spectrum of laboratory and population level
research. Patierno is also actively engaged
Neil Lee Spector
Sandra Coates Associate Professor
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
Gita Suneja
Associate Professor of Radiation Oncology
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info